公开(公告)号：US10105365B2

公开(公告)日：2018-10-23

申请号：US15639424

申请日：2017-06-30

Applicant: AbbVie Inc.

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable ,  Susan George

IPC: A61K31/513 ,  A61K47/38 ,  A61K9/24 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K31/4025

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

公开(公告)号：US09333204B2

公开(公告)日：2016-05-10

申请号：US14677611

申请日：2015-04-02

Applicant: AbbVie Inc. ,  AbbVie Deutschland GmbH & Co. KG

Inventor： Jonathan M. Miller ,  John B. Morris ,  Nancy E. Sever ,  Eric A. Schmitt ,  Ping X. Gao ,  Yi Shi ,  Yi Gao ,  Bernd Liepold ,  Anna Moosmann ,  Mirko Pauli ,  Fatih Durak ,  Thomas Kessler ,  Peter A. Hoelig ,  Karin Rosenblatt ,  Drazen Kostelac ,  Rajeev Gokhale ,  Mark Costello ,  Carl Knable

IPC: A61K31/4965 ,  A01N43/54 ,  A01N43/36 ,  A61K31/513 ,  A61K47/32 ,  A61K47/38 ,  A61K9/24 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497

CPC classification number: A61K31/513 ,  A61K9/209 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.

Abstract translation: 本公开涉及包含抗病毒化合物的固体剂型和使用这些剂型来治疗抗病毒感染的方法。

公开(公告)号：US20150157639A1

公开(公告)日：2015-06-11

申请号：US14537392

申请日：2014-11-10

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/5377 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/4866 ,  A61K31/437 ,  A61K31/496 ,  Y02A50/411

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract translation: 促凋亡固体分散体以基本上非结晶形式包含分散在固体基质中的如本文定义的式I的Bcl-2家族蛋白质抑制化合物，其包含（a）药学上可接受的水溶性聚合物载体和（ b）药学上可接受的表面活性剂。 制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶 形成。 该固体分散体适合于需要其的受试者口服给药以治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。

公开(公告)号：US20140296284A1

公开(公告)日：2014-10-02

申请号：US14107559

申请日：2013-12-16

Applicant: AbbVie Inc.

Inventor： Geoff G. Zhang ,  Douglas H. Hoffman ,  Jonathan M. Miller

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

Abstract translation: 噻吩并[3,2-c]吡啶-3-基}苯基）-N（4- {4-氨基-7- [1-（2-羟乙基）-1H-吡唑-4-基] ' - （3-氟苯基）脲及其结晶形式是用于治疗疾病例如癌症的药物组合物的合适的药物成分。